[go: up one dir, main page]

PE20130578A1 - Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa - Google Patents

Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa

Info

Publication number
PE20130578A1
PE20130578A1 PE2012002474A PE2012002474A PE20130578A1 PE 20130578 A1 PE20130578 A1 PE 20130578A1 PE 2012002474 A PE2012002474 A PE 2012002474A PE 2012002474 A PE2012002474 A PE 2012002474A PE 20130578 A1 PE20130578 A1 PE 20130578A1
Authority
PE
Peru
Prior art keywords
concentration
heparan
sulfatase
compositions
supplying
Prior art date
Application number
PE2012002474A
Other languages
English (en)
Inventor
Farah Natoli
Gaozhong Zhu
Jennifer Terew
Yuan Jiang
Jamie Tsung
Zahra Shahrokh
Brian Vernaglia
Jing Pan
Richard Pfeifer
Pericles Calias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130578(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PE20130578A1 publication Critical patent/PE20130578A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UNA PROTEINA HEPARAN N-SULFATASA (HNS) A UNA CONCENTRACION DE HASTA 100 MG/ML Y COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEC ID Nº: 1; B) UNA SAL TAL COMO CLORURO DE SODIO A UNA CONCENTRACION DE 0 A 300 mM; C) UN AGENTE AMORTIGUADOR TAL COMO FOSFATO A UNA CONCENTRACION NO MAYOR DE 50 mM; D) UN TENSIOACTIVO DE POLISORBATO TAL COMO POLISORBATO 20 A UNA CONCENTRACION DE 0 A 0.05%; Y E) UN AGENTE ESTABILIZANTE TAL COMO SACAROSA A UNA CONCENTRACION DE 0 A 10% O GLUCOSA A UNA CONCENTRACION DE 0.5 A 1%; EN DONDE LA COMPOSICION TIENE UN PH DE 5.0 A 8.0 Y ESTA FORMULADA COMO LIQUIDO O POLVO SECO LIOFILIZADO. DICHA COMPOSICION SE ADMINISTRA INTRATECALMENTE Y ES UTIL EN EL TRATAMIENTO DEL SINDROME DE SANFILIPPO TIPO A
PE2012002474A 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa PE20130578A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PE20130578A1 true PE20130578A1 (es) 2013-05-19

Family

ID=45352777

Family Applications (8)

Application Number Title Priority Date Filing Date
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2018000183A PE20180801A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b
PE2012002474A PE20130578A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2012002479A PE20130637A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2018000183A PE20180801A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b

Family Applications After (3)

Application Number Title Priority Date Filing Date
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2012002479A PE20130637A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos

Country Status (24)

Country Link
US (17) US9814764B2 (es)
JP (22) JP6250616B2 (es)
CN (4) CN106139133B (es)
AR (6) AR081677A1 (es)
BR (1) BR112012033214B1 (es)
CA (1) CA3171308A1 (es)
CL (7) CL2012003656A1 (es)
DK (3) DK3103469T3 (es)
ES (3) ES2858726T3 (es)
HK (1) HK1214149A1 (es)
HR (3) HRP20211520T1 (es)
HU (6) HUE031036T2 (es)
LT (3) LT3103469T (es)
MX (1) MX354776B (es)
NZ (2) NZ702803A (es)
PE (8) PE20130589A1 (es)
PL (1) PL2588130T3 (es)
PT (6) PT2588130T (es)
RS (3) RS62520B1 (es)
RU (1) RU2761342C2 (es)
SI (3) SI3103469T1 (es)
SM (1) SMT201600385B (es)
TW (9) TW201212936A (es)
UA (3) UA129740C2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
PE20130589A1 (es) 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP2793933B1 (en) 2011-12-23 2019-04-17 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
DK3397270T5 (da) * 2015-12-30 2024-09-23 Green Cross Corp Sammensætninger til anvendelse i behandlingen af hunters syndrom
RU2751235C2 (ru) * 2016-02-24 2021-07-12 Байомарин Фармасьютикал Инк. Терапевтические слитые белки направленного действия на основе лизосомных ферментов, соответствующие составы и их применения
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN111801114B (zh) * 2018-02-28 2025-01-07 生化学工业株式会社 包装体及其制造方法
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
JP2020002130A (ja) 2018-06-25 2020-01-09 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
IL309562A (en) 2021-06-21 2024-02-01 Juvena Therapeutics Inc Regenerative polypeptides and their uses
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端
WO2025054521A1 (en) * 2023-09-07 2025-03-13 Juvena Therapeutics, Inc. Igf2 fusion protein formulations and therapeutic uses thereof
WO2025075929A1 (en) * 2023-10-02 2025-04-10 Neurona Therapeutics Inc. Methods of treating seizure activity

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
AU695125B2 (en) * 1993-02-02 1998-08-06 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
AU735216B2 (en) 1997-08-22 2001-07-05 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
JP4990434B2 (ja) 1998-12-07 2012-08-01 ジェンザイム・コーポレーション ポンペ病の処置
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US7412285B2 (en) 1999-04-09 2008-08-12 Oncostim, Inc. Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
IL158623A0 (en) 2001-04-30 2004-05-12 Symbiontics Inc Subcellular targeting of therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030040479A1 (en) 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030181426A1 (en) 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
EP1426069A1 (en) 2002-12-02 2004-06-09 Diana Evelyn Miller Drug delivery system
EP1587923B1 (en) 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
ES2545619T3 (es) 2003-01-31 2015-09-14 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
WO2004069870A2 (en) 2003-02-10 2004-08-19 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
NZ589037A (en) 2004-01-30 2011-10-28 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP1716232B9 (en) 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
UA11577U (en) 2004-04-21 2006-01-16 Academician A P Romodanov Inst Device for intrathecal drug administration into spinal canal
KR20070037444A (ko) * 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 고체 미립자성 치료제의 생체외 적용방법
ATE451472T1 (de) * 2004-08-11 2009-12-15 Basf Se Zeit-temperatur-indikator auf enzymbasis
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
US20090297592A1 (en) * 2005-05-11 2009-12-03 Jcr Pharmaceuticals Co., Ltd. Lipid Vesicle Composition
CA2611011C (en) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA3168881C (en) 2006-02-09 2025-09-09 Genzyme Corporation SLOW INTRAVENTRICULAR ADMINISTRATION
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
PT2628746T (pt) 2006-04-04 2019-04-23 Chiesi Farm Spa Um processo para a concentração de um polipéptido
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
US8419710B2 (en) * 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
WO2008109677A2 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
EP2174661B1 (en) 2007-06-29 2012-12-19 National University Corporation Nagoya University Agent for improving neuropathic pain
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US8470771B2 (en) * 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
US9320711B2 (en) * 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
RS59469B1 (sr) 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
AU2011270672B2 (en) 2010-06-25 2017-01-12 Shire Human Genetic Therapies, Inc. Treatment of Sanfilippo Syndrome type B
PE20130589A1 (es) 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10603364B2 (en) 2014-08-11 2020-03-31 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
AU2015301809A1 (en) 2014-08-11 2017-02-02 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
MA40791A (fr) 2014-10-24 2017-09-27 Shire Human Genetic Therapies Ciblage lysosomal d'enzymes et utilisations associées
US9673835B1 (en) 2015-12-04 2017-06-06 Taiwan Semiconductor Manufacturing Co., Ltd. Pipelined SAR with TDC converter

Also Published As

Publication number Publication date
CN104857504A (zh) 2015-08-26
MX354776B (es) 2018-03-20
US20170042977A1 (en) 2017-02-16
US20220133862A1 (en) 2022-05-05
RU2761342C2 (ru) 2021-12-07
JP2020079297A (ja) 2020-05-28
JP2016040337A (ja) 2016-03-24
TWI876260B (zh) 2025-03-11
AR081681A1 (es) 2012-10-10
ES2895655T3 (es) 2022-02-22
RU2017125281A (ru) 2019-01-31
JP6898909B2 (ja) 2021-07-07
HUE031036T2 (en) 2017-06-28
US20190183984A1 (en) 2019-06-20
CN106139133B (zh) 2020-12-04
JP2019038853A (ja) 2019-03-14
PT3103469T (pt) 2021-03-04
NZ702803A (en) 2017-05-26
CL2012003656A1 (es) 2013-07-19
TWI790444B (zh) 2023-01-21
JP2023052868A (ja) 2023-04-12
JP6285409B2 (ja) 2018-02-28
JP2019031575A (ja) 2019-02-28
CN105233277A (zh) 2016-01-13
RS62520B1 (sr) 2021-11-30
US20200046810A1 (en) 2020-02-13
CN105664142A (zh) 2016-06-15
SI3626258T1 (sl) 2021-11-30
JP7087175B2 (ja) 2022-06-20
US12409210B2 (en) 2025-09-09
US20250121040A1 (en) 2025-04-17
PE20180801A1 (es) 2018-05-09
TW201726161A (zh) 2017-08-01
JP7591476B2 (ja) 2024-11-28
JP6797876B2 (ja) 2020-12-09
AR081678A1 (es) 2012-10-10
JP7448507B2 (ja) 2024-03-12
UA125060C2 (uk) 2022-01-05
AR081679A1 (es) 2012-10-10
SI3626257T1 (sl) 2021-12-31
US9220677B2 (en) 2015-12-29
JP2016041755A (ja) 2016-03-31
TW201701899A (zh) 2017-01-16
TWI602573B (zh) 2017-10-21
PT3626257T (pt) 2021-11-12
CN106139133A (zh) 2016-11-23
US20250375506A1 (en) 2025-12-11
CL2012003655A1 (es) 2013-04-19
TW201815411A (zh) 2018-05-01
BR112012033214A2 (pt) 2017-05-23
LT3626257T (lt) 2021-12-10
US10646554B2 (en) 2020-05-12
US11471516B2 (en) 2022-10-18
SMT201600385B (it) 2017-03-08
RU2018137304A3 (es) 2022-02-22
SI3103469T1 (sl) 2021-04-30
RU2018137304A (ru) 2019-03-21
ES2896060T3 (es) 2022-02-23
US20200113981A1 (en) 2020-04-16
JP2018002735A (ja) 2018-01-11
NZ702800A (en) 2017-03-31
US12161702B2 (en) 2024-12-10
JP2021167340A (ja) 2021-10-21
LT3103469T (lt) 2021-03-25
US20170042978A1 (en) 2017-02-16
TW201206465A (en) 2012-02-16
BR112012033214B1 (pt) 2020-11-03
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
US11065307B2 (en) 2021-07-20
PE20180130A1 (es) 2018-01-18
RU2018113327A (ru) 2019-03-01
HUE046856T2 (hu) 2020-03-30
PT2585104T (pt) 2019-10-30
PE20170938A1 (es) 2017-07-13
JP7359827B2 (ja) 2023-10-11
JP2023062114A (ja) 2023-05-02
HK1214149A1 (zh) 2016-07-22
JP2020079244A (ja) 2020-05-28
TWI669128B (zh) 2019-08-21
CL2020000468A1 (es) 2020-09-04
HRP20210298T1 (hr) 2021-04-16
JP2016037504A (ja) 2016-03-22
JP6522073B2 (ja) 2019-05-29
US11260112B2 (en) 2022-03-01
US20180085438A1 (en) 2018-03-29
PE20130579A1 (es) 2013-05-19
CA3171308A1 (en) 2011-12-29
CL2012003657A1 (es) 2013-04-19
DK3626258T3 (da) 2021-09-20
US20180071212A1 (en) 2018-03-15
MX2013000321A (es) 2013-04-03
JP2023099216A (ja) 2023-07-11
PL2588130T3 (pl) 2017-09-29
HUE046409T2 (hu) 2020-02-28
TW202506172A (zh) 2025-02-16
CN105233277B (zh) 2019-01-01
RU2018113327A3 (es) 2021-07-21
US20140271598A1 (en) 2014-09-18
JP6938456B2 (ja) 2021-09-22
JP6250616B2 (ja) 2017-12-20
JP2024097029A (ja) 2024-07-17
CL2016003159A1 (es) 2017-05-12
RS61683B1 (sr) 2021-05-31
PE20130637A1 (es) 2013-06-13
CL2017002488A1 (es) 2017-12-15
HUE055963T2 (hu) 2022-01-28
DK3103469T3 (en) 2021-02-22
TWI698252B (zh) 2020-07-11
PE20130589A1 (es) 2013-05-19
RS62620B1 (sr) 2021-12-31
US20200405825A1 (en) 2020-12-31
TW202112391A (zh) 2021-04-01
HRP20211660T1 (hr) 2022-02-04
PT2593131T (pt) 2019-10-30
HUE056884T2 (hu) 2022-03-28
US11065308B2 (en) 2021-07-20
AR081680A1 (es) 2012-10-10
JP2017214434A (ja) 2017-12-07
JP6466538B2 (ja) 2019-02-06
PT3626258T (pt) 2021-10-19
JP2020079298A (ja) 2020-05-28
DK3626257T3 (da) 2021-11-08
JP2016094451A (ja) 2016-05-26
JP7543459B2 (ja) 2024-09-02
US20250161417A1 (en) 2025-05-22
US20230026836A1 (en) 2023-01-26
US20160158324A1 (en) 2016-06-09
JP2021167341A (ja) 2021-10-21
PT2588130T (pt) 2016-11-25
UA125743C2 (uk) 2022-06-01
US20230165942A1 (en) 2023-06-01
JP6522072B2 (ja) 2019-05-29
AR082025A1 (es) 2012-11-07
JP2022024176A (ja) 2022-02-08
PE20130648A1 (es) 2013-07-03
US12168041B2 (en) 2024-12-17
TW202337489A (zh) 2023-10-01
US10456454B2 (en) 2019-10-29
LT3626258T (lt) 2021-12-10
HK1218719A1 (zh) 2017-03-10
US12121569B2 (en) 2024-10-22
US20130295077A1 (en) 2013-11-07
ES2858726T3 (es) 2021-09-30
JP2018002734A (ja) 2018-01-11
US9814764B2 (en) 2017-11-14
CL2012003654A1 (es) 2013-06-14
HRP20211520T1 (hr) 2021-12-24
TW201825111A (zh) 2018-07-16
HUE052944T2 (hu) 2021-05-28
JP2021181489A (ja) 2021-11-25
JP2016040335A (ja) 2016-03-24
RU2017125281A3 (es) 2020-11-09
AR081677A1 (es) 2012-10-10
JP6346162B2 (ja) 2018-06-20
JP2019006826A (ja) 2019-01-17
UA129740C2 (uk) 2025-07-23

Similar Documents

Publication Publication Date Title
PE20130578A1 (es) Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE20230169A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
AR117403A2 (es) Formulaciones de anticuerpos
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
AR094178A1 (es) Derivados de exendina-4 funcionalizada
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
PE20141265A1 (es) Formulaciones liofilizadas de fgf-18
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
AR095451A1 (es) Formulación de anticuerpos
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
AR081200A1 (es) Formulaciones de insulina de accion prolongada
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2017101667A (ru) Фармацевтические композиции
NZ593190A (en) Factor viii formulations
PE20120788A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos
PE20121528A1 (es) Metodos para administrar agentes hipoglucemiantes de larga duracion
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
PE20142275A1 (es) Formulacion de anticuerpo il-17
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc

Legal Events

Date Code Title Description
FC Refusal